Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) issued its earnings results on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), Zacks reports. During the same period in the prior year, the company posted ($0.28) earnings per share.
Acumen Pharmaceuticals Stock Performance
Shares of ABOS opened at $3.81 on Wednesday. The company has a quick ratio of 30.20, a current ratio of 30.20 and a debt-to-equity ratio of 0.12. Acumen Pharmaceuticals has a 12 month low of $1.81 and a 12 month high of $11.31. The company’s fifty day moving average is $3.69 and its 200-day moving average is $3.40. The firm has a market cap of $228.90 million, a price-to-earnings ratio of -3.59 and a beta of 0.19.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Acumen Pharmaceuticals in a report on Wednesday, May 15th.
Acumen Pharmaceuticals Company Profile
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Featured Stories
- Five stocks we like better than Acumen Pharmaceuticals
- ESG Stocks, What Investors Should Know
- Eagle Materials Stock is Dipping, Results Say Not for Long
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- The Only A-Rated Stock with a 7%+ Dividend
- Why Invest in High-Yield Dividend Stocks?
- 3 Financial Stocks Outperforming as The Fed Dumps Bonds
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
